Teva agrees to pay Baltimore City $80m for fuelling opioid epidemic
Pharmaceutical Technology
SEPTEMBER 10, 2024
Baltimore opted out of a national settlement last year, instead pursuing its own claim against the opioid manufacturer.
Tue.Sep 10, 2024
264 
Scientists Reveal The Absolute Worst Thickness For a Paper Cut
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 10, 2024
(cookiecatagency/Getty Images) It’s happened to the best of us. There you are, minding your own business, sealing envelopes or replacing the printer ream, and tsssss ouch! A freshly minted paper cut, oozing ruby-red human juice, all over the clean white surface.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
EASD 2024: New developments in presymptomatic type 1 diabetes screening
Pharmaceutical Technology
SEPTEMBER 10, 2024
The study involved over 3,600 participants, including FDRs of newly diagnosed type 1 diabetes patients in Denmark and children in Sweden.
Investors are waking up to Centessa’s sleepiness drug
Bio Pharma Dive
SEPTEMBER 10, 2024
A small, early study produced what one analyst called “highly compelling” results that lifted the company’s shares by as much as 15% Tuesday.
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
DoP to frame ‘Disposal Policy’ for safe removal of unused and expired drugs from household & sale premises
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 10, 2024
In order to avoid environmental hazards due to pharmaceutical products, the Department of Pharmaceuticals (DoP) is thinking of framing a ‘Disposal Policy’ for removing the unused and date-expired drugs from the sale premises and from the households.
House backs bill restricting China role in US biotech
Bio Pharma Dive
SEPTEMBER 10, 2024
The Biosecure Act, which limits contracts with WuXi AppTec, WuXi Biologics and three other companies, still needs Senate support to advance.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
New data add to doubts about AstraZeneca, Daiichi’s Enhertu successor
Bio Pharma Dive
SEPTEMBER 10, 2024
The partners’ ADC didn’t significantly extend survival in lung cancer patients who were expected to benefit the most from treatment in a Phase 3 trial.
US bill passed to restrict business with Chinese biotech companies
Pharmaceutical Technology
SEPTEMBER 10, 2024
The US House of Representatives has passed a bill to restrict business with certain Chinese biotech companies.
APL and CurifyLabs partner to support patients with 3D printing medicine technology
Pharma Times
SEPTEMBER 10, 2024
Critically ill individuals will benefit from futuristic tech
Bain closes $3B biotech fund amid flurry of startup buyouts
Bio Pharma Dive
SEPTEMBER 10, 2024
The fund is Bain’s fourth and follows several recent acquisitions of some of its portfolio companies, among them Jnana Therapeutics and EyeBio.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Phase 2 PREDICT-ILD imaging study commences in interstitial lung disease
Pharma Times
SEPTEMBER 10, 2024
Molecular imaging agent 99mTc-maraciclatide to aid in disease prognostication
EASD 2024: Eli Lilly releases Phase III data for once-weekly insulin in diabetes
Pharmaceutical Technology
SEPTEMBER 10, 2024
Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.
Neuromuscular diseases in crosshairs in Forge Biologics gene therapy collaboration
BioPharma Reporter
SEPTEMBER 10, 2024
Forge Biologics will help with the manufacturing of adeno-associated viruses (AAVs) in a collaboration with the non-profit Muscular Dystrophy Association (MDA) to develop gene therapies for neuromuscular diseases.
T-cell targeting Candid Therapeutics launches with $370m
Pharmaceutical Technology
SEPTEMBER 10, 2024
The new biotech has inherited two T cell engager antibodies as part of a three-way merger with Vignette and TRC 2004.
Life sciences real estate is booming amid looming ‘patent cliff’, but what lies ahead?
pharmaphorum
SEPTEMBER 10, 2024
Investment in life sciences real estate is booming as the industry faces the looming 'patent cliff' Learn about the current trends and what lies ahead for this sector.
EASD24: Eli Lilly releases Phase III data for once-weekly insulin in diabetes
Pharmaceutical Technology
SEPTEMBER 10, 2024
Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.
Pharma Pulse 9/10/24: Counterfeit Weight Loss Drugs & Potential Health Risks, AI Isn't Magic & more
Pharmaceutical Commerce
SEPTEMBER 10, 2024
The latest news for pharma industry insiders.
EASD 2024: Novel insights into maternal protection in T1D
Pharmaceutical Technology
SEPTEMBER 10, 2024
At EASD 2024, meta-analysis results shed new light on the genetic transmission of type 1 diabetes (T1D) from parents to offspring.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
GSK’s Depemokimab Significantly Reduces Asthma Exacerbations
Pharmaceutical Commerce
SEPTEMBER 10, 2024
A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.
Vir Biotechnology closes Sanofi licence deal for T-cell engagers
Pharmaceutical Technology
SEPTEMBER 10, 2024
Vir Biotechnology has concluded a deal with Sanofi, enabling access to multiple T-cell engages and the PRO-XTEN masking platform.
Ready-to-Use Boruzu (Bortezomib) from Amneal and Shilpa Approved by FDA
XTalks
SEPTEMBER 10, 2024
Amneal Pharmaceuticals and Shilpa Medicare have announced US Food and Drug Administration (FDA) approval of Boruzu, a ready-to-use formulation of bortezomib for subcutaneous or intravenous (IV) administration. Boruzu, a proteasome inhibitor, offers a more efficient approach to treating multiple myeloma and mantle cell lymphoma by eliminating the reconstitution process required for Velcade, the current branded version of bortezomib.
Integrated Nanotherapeutics gains funds for new T1D treatment
Pharmaceutical Technology
SEPTEMBER 10, 2024
Integrated Nanotherapeutics secured funds to propel the development of an immune tolerizing therapeutic for Type 1 diabetes.
Optimizing Partnerships for Generic Drug Development Success
Drug Patent Watch
SEPTEMBER 10, 2024
The generic drug market has experienced significant growth over the past few decades, driven by the passage of the Hatch-Waxman Act in 1984 and subsequent legislation. Today, the market is more competitive than ever, with generic drugs accounting for over 90% of all prescriptions in the United States.
Creyon Bio secures second patent for AI-powered oligonucleotide engineering
BioPharma Reporter
SEPTEMBER 10, 2024
Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based medicines (OBMs), recently announced the issuance of its second US patent.
After BIOSECURE Act passes in House, targeted Chinese companies say they're 'deeply' concerned
Fierce Pharma
SEPTEMBER 10, 2024
After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold. | Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics.
Candid Therapeutics launches with $370m to tackle autoimmunity with T-cell engagers
BioPharma Reporter
SEPTEMBER 10, 2024
The San Diego-based biotech company Candid Therapeutics has launched with a huge $370 million with the aim to develop T-cell engager therapies for autoimmune diseases.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
WCLC: Bayer, Boehringer face off on HER2 cancers
pharmaphorum
SEPTEMBER 10, 2024
Bayer and Boehringer present data on competing oral HER2 drugs at WCLC, as they run phase 3 trials in NSCLC with HER2 activations.
Therapy for aggressive brain cancer receives FDA clearance to start phase 1
BioPharma Reporter
SEPTEMBER 10, 2024
Adaptin Bio has announced that the FDA has given the green light to start phase 1 clinical trials for its program APTN-101 targeting glioblastoma, the most common and aggressive form of brain cancer.
Pharma companies must prioritize patient reach, report says
Outsourcing Pharma
SEPTEMBER 10, 2024
Pharmaceutical companies are under increasing pressure to ensure that essential healthcare products are accessible to all, regardless of socioeconomic status or location.
Terns files $125m financing after positive obesity data
pharmaphorum
SEPTEMBER 10, 2024
Terns Pharma files $125m+ public offering to support trials of its oral GLP-1 agonist candidate TERN-601 for obesity.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Let's personalize your content